Reversible Nyctalopia and Retinopathy in a Patient With Metastatic Cancer Treated With Anti–Heat Shock Protein 90 Therapy

Cancer-associated retinopathy is an autoimmune disease in which autoantibodies trigger retinal tissue destruction.¹ Patients with cancer-associated retinopathy may develop visual acuity or visual field loss, photopsias, photophobia, and/or nyctalopia.¹ Drug-induced toxic effects can also cause photoreceptor damage and corresponding visual symptoms.² We describe a patient with nyctalopia during treatment of non–small cell lung cancer with AUY922, a heat shock protein 90 (HSP90) inhibitor.³